Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

We’ve updated this story to clarify how messages are stored in backups. If you don’t want your text messages read by prying eyes, you should consider locking your phone with a passcode or ...

If you want to know who really controls KSB SE & Co. KGaA (ETR:KSB), then you'll have to look at the makeup of its share registry. We can see that private companies own the lion's share in the ...

Jan 30 (Reuters) - Merck (MRK.N), opens new tab plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in ...

If you want to know who really controls KSB SE & Co. KGaA (ETR:KSB), then you'll have to look at the makeup of its share registry. We can see that private companies own the lion's share in the company ...

We tested a range of AI-detection services with text written by ChatGPT and text written by a human: These are the tools that performed best. My title is Senior Features Writer, which is a license ...

DAVOS, Switzerland, Jan 23 (Reuters) - The CEO of Germany's Merck KGaA (MRCG.DE), opens new tab on Thursday said a recovery in sales growth at its existing business means it can take a cautious ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the introduction of a Caregiver Leave Benefit as an additional family ...

Belén Garijo, CEO of Merck KGaA, weighs in on Europe's competitiveness and the pharma giant's preparations for the impact of potential U.S. trade tariffs. Trump won't block immigration arrests in ...

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed. By Christina Jewett and Sheryl Gay Stolberg ...

Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028.